References
  1. 1.Guan WJ Ni ZY Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032
  2. .Zhang C Shi L Wang FS Liver injury in COVID-19: management and challenges.Lancet Gastroenterol Hepatol. 2020; (published online March)https://doi.org/10.1016/S2468-1253(20)30057-1
  3. Huang C Wang Y Li X et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020; 395: 497-506
  4. Marrie RA et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology. 2014; 83: 929‐ 937.
  5. Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol. 2013; 20: 1153‐ 1160.
  6. Wijnands JM et al. Infection‐related health care utilization among people with and without multiple sclerosis. Mult Scler. 2016; https://doi.org/10.1177/1352458516681198. Epub ahead of print
  7. Smestad C, Sandvik L, Celius EG. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients. Mult Scler. 2009; 15: 1263‐ 1270.
  8. Wijnands JMA et al. Health‐care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 2017; 16: 445‐ 451.
  9. Bruck W et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013; 70: 1315‐ 1324.
  10. Global, regional, and national life expectancy, all‐cause mortality, and cause‐specific mortality for 249 causes of death, 1980‐2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459‐ 1544.
  11. Williamson EM, Berger JR. Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs. 2015; 29: 229‐ 244.
  12. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol. 1993; 240: 417‐ 422.
  13. Faissner S, Gold R Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs. 2018 Mar;32(3):269-287. doi: 10.1007/s40263-018-0488.
  14. Ellen Lu et al. Safety of disease-modifying drugs for multiplesclerosis in pregnancy: current challengesand future considerations for effectivepharmacovigilance. Expert Review of Neurotherapeutics.
  15. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet Lond. Engl. 1998;352:1498–1504.
  16. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dosecomparison study of weekly interferon beta-1a in relapsing MS.Neurology. 2002;59:1507–1517.
  17. Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.Neurology. 2011;77:1684–1690.
  18. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet Lond. Engl. 2001;357:1576–1582.
  19. Davis MD, Ashtamker N, Steinerman JR, et al. Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. Neurol. Neuroimmunol. Neuroinflammation [Internet]. 2017 [cited 2019 Jul 25];
  20. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–1276.
  21. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet Lond. Engl. 2009;374:1503–1511.
  22. D’Amico E, Leone C, Caserta C, et al. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev. Neurother. 2015;15:803–824.
  23. Oh J, O’Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. Ther. Adv. Neurol. Disord. 2014;7:239–252.
  24. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011;365:1293– 1303.
  25. Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Neurol. 2014;13:247–256.
  26. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977–986.
  27. O’Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86:920–930. [
  28. Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther. Adv. Chronic Dis. 2016;7:198– 207.
  29. Diebold M, Altersberger V, Décard BF, et al. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult. Scler. Houndmills Basingstoke Engl. 2019;1352458519852100.
  30. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–556.
  31. Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J. Neurol. Neurosurg. Psychiatry. 2016;87:468–475.
  32. Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011;69:759–777.
  33. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 2010;362:416–426.
  34. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult. Scler. Houndmills Basingstoke Engl. 2011;17:578–593